The present disclosure provides a composition including trifluoroacetyl iodide, at least one organic impurity and at least one inorganic impurity. The at least one organic impurity includes at least one of: difluoroiodomethane, pentafluoroiodoethane, iodomethane, iodopropane, dichlorotetrafluoroethane, dichlorotrifluoroethane, trichlorotrifluoroethane, methyltrifluoroacetate, trifluoroacetic anhydride, difluorobutane and methyl propane. The at least one inorganic impurity includes at least one of: hydrogen iodide, hydrogen chloride, iodine and hydrogen triiodide.

The present disclosure provides a composition including trifluoroacetyl iodide, at least one organic impurity and at least one inorganic impurity. The at least one organic impurity includes at least one of: difluoroiodomethane, pentafluoroiodoethane, iodomethane, iodopropane, dichlorotetrafluoroethane, dichlorotrifluoroethane, trichlorotrifluoroethane, methyltrifluoroacetate, trifluoroacetic anhydride, difluorobutane and methyl propane. The at least one inorganic impurity includes at least one of: hydrogen iodide, hydrogen chloride, iodine and hydrogen triiodide.

In some aspects, the present disclosure provides compounds of the formula: ##STR00001##
wherein the variables are defined herein. In some aspects, the present disclosure provides methods of preparing imaging agents, compositions thereof, and methods of imaging using said imaging agents or compositions thereof.

In some aspects, the present disclosure provides compounds of the formula: ##STR00001##
wherein the variables are defined herein. In some aspects, the present disclosure provides methods of preparing imaging agents, compositions thereof, and methods of imaging using said imaging agents or compositions thereof.

A complex having the structure of formula (I) ##STR00001##
is disclosed. L.sub.1, L.sub.2, L.sub.3, L.sub.4, and L.sub.5 may be or include independently metal-coordinating ligands selected from the group consisting of neutral ligands, anionic ligands, and mixed ligands, and combinations thereof. In a non-limiting embodiment, the complex is an N-heterocyclic carbene (NHC) Re(I) complex having an unsubstituted or substituted benzimidazol-2-ylidene ligand. The complex may be included in a pharmaceutical composition for treating gram (+) bacterial infections.

A complex having the structure of formula (I) ##STR00001##
is disclosed. L.sub.1, L.sub.2, L.sub.3, L.sub.4, and L.sub.5 may be or include independently metal-coordinating ligands selected from the group consisting of neutral ligands, anionic ligands, and mixed ligands, and combinations thereof. In a non-limiting embodiment, the complex is an N-heterocyclic carbene (NHC) Re(I) complex having an unsubstituted or substituted benzimidazol-2-ylidene ligand. The complex may be included in a pharmaceutical composition for treating gram (+) bacterial infections.

Described herein are hydrophobic compositions including a hydrophilic active ingredient and to methods of making and using the same.

A composition comprising the following structure: (1) wherein Re represents a rhenium ion having a +1 charge; (I) represents an uncharged bidentate ligand containing at least one ring containing a ring nitrogen atom bound to the rhenium (Re), and the bidentate ligand containing another nitrogen atom, either in a ring or not in a ring, bound to the rhenium (Re); and L.sup.1, L.sup.2, L.sup.3, and L.sup.4 are neutral ligands with at least one neutral ligand being an isonitrile ligand of the formula —CN—R, wherein R is an aliphatic or aromatic hydrocarbon group containing 1-20 carbon atoms; and X.sup.− represents a non-coordinating monovalent anion; wherein the bidentate ligand and R are optionally substituted by one or more groups selected from (i)-(xi) as further discussed above. Methods for treating a condition that benefits from ER stress induction, such as cancer, by administering the above rhenium complex are also disclosed.

A composition comprising the following structure: (1) wherein Re represents a rhenium ion having a +1 charge; (I) represents an uncharged bidentate ligand containing at least one ring containing a ring nitrogen atom bound to the rhenium (Re), and the bidentate ligand containing another nitrogen atom, either in a ring or not in a ring, bound to the rhenium (Re); and L.sup.1, L.sup.2, L.sup.3, and L.sup.4 are neutral ligands with at least one neutral ligand being an isonitrile ligand of the formula —CN—R, wherein R is an aliphatic or aromatic hydrocarbon group containing 1-20 carbon atoms; and X.sup.− represents a non-coordinating monovalent anion; wherein the bidentate ligand and R are optionally substituted by one or more groups selected from (i)-(xi) as further discussed above. Methods for treating a condition that benefits from ER stress induction, such as cancer, by administering the above rhenium complex are also disclosed.

The invention comprises novel chiral metal complex compounds of the formula ##STR00001## wherein M, PR.sup.2, R.sup.3 and R.sup.4 are outlined in the description, its stereoisomers, in the form as a neutral complex or a complex cation with a suitable counter ion. The chiral metal complex compounds can be used in asymmetric reactions, particularly in asymmetric reductions of ketones, imines or oximes.